17 results on '"Skalland M"'
Search Results
2. 224 Elexacaftor/tezacaftor/ivacaftor alters gastrointestinal symptoms and inflammation: Report of PROMISE Pediatric Gastrointestinal Study
3. 173 Effectiveness of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: The pediatric PROMISE study
4. Antipseudomonal treatment decisions during CF exacerbation management
5. C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response
6. Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation
7. WS01.01 Antipseudomonal treatment decisions during cystic fibrosis exacerbation management
8. 209: Elexacaftor/tezacaftor/ivacaftor alters gastrointestinal symptoms: Six-month report of PROMISE GI
9. 157: C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response
10. 153: Site of intravenous antimicrobial treatment of pulmonary exacerbations in the STOP2 study: Home versus hospital
11. WS09.6 A randomised clinical trial of antimicrobial duration for treatment of cystic fibrosis pulmonary exacerbations (STOP2)
12. Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment
13. WS04.3 Changes in symptom scores as a potential clinical endpoint for studies of pulmonary exacerbation treatment
14. WS01-3 IV gallium nitrate demonstrates biological activity for chronic Pseudomonas aeruginosa infection in cystic fibrosis
15. P094 Design, enrollment, and feasibility of the STOP-2 randomised study of intravenous antibiotic treatment duration in cystic fibrosis pulmonary exacerbations
16. WS05.3 New Pseudomonas chronicity score: evaluating association with clinical outcomes and comparing to Leeds criteria
17. Absence of rebound from diltiazem therapy in Prinzmetal's variant angina
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.